COMPASS Pathways plc

NASDAQ:CMPS

Medical - Care Facilities

Healthcare
$8.12 +0.16%

+$0.02 today

Market cap
$1.15B
Beta
2.51
P/E (TTM)
-7.4
EPS (TTM)
-$1.63
52W Low $2.25High $14.76

Volume 2.35M

Average 4.09M

CMPS Debt Repayment

Cash used to repay borrowings during the period.

COMPASS Pathways plcNASDAQ: CMPS

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $18.55M

Q1 FY2026 debt repayment was $18.55M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $18.55M.

Context

  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $18.55M or moves back toward the trailing-twelve-month quarterly average of $4.64M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.55M— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$18.55M— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Debt Repayment vs competitors

How CMPS compares with its peers on the latest reported figures

  • CMPS's LTM Mar 2026 debt repayment of $18.55M is the 2nd largest of the 11 companies compared; the peer median is $0.
CMPS Competitors Peer median
Debt Repayment for CMPS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$18.75M +25.0%+101.0%2.0%
CMPSCOMPASS Pathways plcLTM Mar 2026$18.55M ———
DNLIDenali Therapeutics Inc.LTM Jun 2026$1.38M -96.5%—38.2%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$832K +949.0%——
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$259.19K -101.2%——
GHRSGH Research PLCLTM Mar 2026$63K -73.0%——
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$0 ——0.0%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$0 ———
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$0 ——0.0%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$0 ———
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
Peer median (excluding CMPS) $0-73.0%+101.0%1.0%

Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.74M)(91.51M)(118.46M)(155.12M)(287.86M)
Depreciation & Amortization175K330K242K233K216K
Deferred Income Tax22K0000
Stock-Based Compensation8.64M13.12M17.28M19.52M13.59M
Change in Working Capital(6.64M)(30.67M)3.48M11.72M(14.28M)
Accounts Receivables00000
Inventory00000
Accounts Payables(163K)2.5M864K6.59M2.03M
Other Working Capital(6.47M)(33.16M)2.62M5.13M(16.32M)
Other Non-Cash Items1.8M3.27M86K4.46M131.1M
Operating Cash Flow(67.75M)(105.45M)(97.38M)(119.19M)(157.24M)
Capital Expenditures(334K)(596K)(66K)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities002K00
Investing Cash Flow(334K)(596K)(64K)00
Debt Repayment0029.59M00
Common Stock Issued154.79M440K144.94M26.22M141.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.85M600K(690K)37.61M(328.83K)
Financing Cash Flow156.65M1.04M173.83M63.82M140.71M
Effect of Forex Changes(5.58M)(24.96M)867K194K1.05M
Net Change in Cash82.99M(129.97M)77.26M(55.17M)(15.48M)
Free Cash Flow(68.08M)(106.05M)(97.44M)(119.19M)(157.24M)

COMPASS Pathways plc

NASDAQ:CMPS

Intrinsic Alpha fair value

Locked

Current Price

$8.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.